Search

Author/Creator Matulonis, U.A.

1. Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models. (December 2016)

Authors:
O'Connor, M.J.; Odedra, R.; Palakurthi, S.; Hughes, A.; Lai, Z.; Kirschmeier, P.; Zeng, Q.; Zhou, S.; Dharma, S.; Ivanova, E.; Wang, A.; Pierce, A.J.; Yates, J.; Powell, S.; Dougherty, B.; Barrett, J.C.; English, J.; Jewsbury, P.; Matulonis, U.A.; Liu, J.F.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S142
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity in BRCA mutant cancers with intrinsic or acquired resistance to PARP inhibitors. (October 2022)

Authors:
Cadzow, L.; Gokhale, P.C.; Ganapathy, S.; Sullivan, P.; Nayak, S.; Shenker, S.; Schlabach, M.; Tobin, E.; Matulonis, U.A.; Liu, J.F.; Stegmeier, F.; Wylie, A.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S37
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search